everolimus Afinitor TSC
Selected indexed studies
- ** (, 2017) [PMID:30222273]
- Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. (Eur J Paediatr Neurol, 2023) [PMID:37669572]
- Everolimus. (Recent Results Cancer Res, 2018) [PMID:30069763]
_Worker-drafted node — pending editorial review._
Connections
everolimus Afinitor TSC is a side effect of
Sources
- Rapamycin for longevity: the pros, the cons, and future perspectives. (2025) pubmed
- Everolimus. (2018) pubmed
- Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. (2023) pubmed
- Tuberous sclerosis: a review of the past, present, and future. (2020) pubmed
- Everolimus. (2014) pubmed
- Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. (2023) pubmed
- PMID:30222273 (2017) pubmed
- Tuberous sclerosis complex. (2018) pubmed
- Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. (2024) pubmed
- [Lymphangioleiomyomatosis]. (2013) pubmed